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1. Introduction 
The synthesis and supply of isotopically-labelled molecules 
has a sustained importance in the study of preparative chemistry, 
reaction mechanisms, and metabolic processes, with documented 
uses spanning a range of physical organic, organometallic, and 
pharmaceutical chemical sciences.
1
 In one particularly active 
branch of such research, hydrogen isotope exchange (HIE) is 
commonly employed to deliver deuterium (D) or radioactive 
tritium (T) to pharmaceutical drug candidates in one synthetic 
step.
2
 As well as circumventing the requirement for isotopically-
enriched starting materials in synthesising tritiated drug 
candidates,
2f,g
 HIE can also provide deuterated analogues for use 
as internal standards for mass spectrometry,
3
 for kinetic isotope 
studies,
1
 and for the alteration of reaction pathways in total 
syntheses.
4 
Recently, one of our laboratories has focused on the 
development and understanding of ortho-directed HIE C-H 
activation processes using homogeneous iridium(I) complexes of 
the type 1 (Fig. 1).
5
 Owing to the steric bulk and electron-
donating power of the NHC/phosphine combination, these 
complexes have been shown to be significantly more active in the 
direct introduction of both D and T
5a,c
 and produce less 
radioactive waste
2c
 than in tritiations with commonly-used 
&UDEWUHH¶VFDWDO\VW>&2',U3&\3)(py)]PF6, 5. 
 
Fig. 1. HIE catalysts bearing an NHC-phosphine ligand sphere. 
 
Although we have shown these catalysts to be compatible with 
a range of directing groups routinely present in drug-like 
compounds, the focus has been mainly on ketones, amides, and 
nitro compounds.
5a,c
 To date, we have explored comparatively 
few N-heterocyclic directing groups,
5c
 despite the prevalence of 
such moieties in drug candidates. In this contribution, we explore 
the compatibility of complexes 1a-c with an appreciably 
enhanced array of N-heterocyclic directing groups for the ortho-
deuteration of pharmaceutically-relevant aromatic compounds. 
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Fig. 2. Deuteration of phenyl N-heterocycles with catalysts 1a±c. Conditions: 
Substrate (0.086 mmol), [Ir] (0.0043 mmol, 5 mol%), DCM (1 mL), D2 (1 
atm), 25 ºC, 1 h. Deuterium incorporation measured by 1H NMR and LC-MS 
(see ESI for details). The results shown are an average of two independent 
reaction runs. 
2. Results and Discussion 
Our studies began with the application of heteroaryl 
functionalised benzene derivatives, 6±11, with complexes 1a±c 
under the mild reaction conditions developed for use with these 
catalyst systems (Figure 2). We were encouraged to find that, in 
all cases, at least one catalyst from 1a±c was able to install 
>80%D in the phenyl ring adjacent to the N-heterocyclic 
directing group. Importantly, all isotopically labelled products 
were recovered in excellent yields. In the pyrimidine, 6, catalyst 
1a was able to deliver excellent 93% deuteration to the expected 
ortho-positions, with this Ir species being found to be 
significantly more efficient than catalysts 1b and 1c. For 
imidazole 7, oxazole 8, oxazoline 9, isoxazole 10, and thiazole 
11, all three catalysts delivered moderate to excellent levels of 
deuterium incorporation. Again, catalyst 1a was found to be the 
most efficient, except in the case of isoxazole 10, where complex 
1b was most productive. 
To further expand the substrates compatible with catalysts 1a±
c for effective HIE, we studied the deuteration of benzannulated 
compounds, 12±15 (Figure 3). For benzimidazole, 12, no 
deuterium incorporation was detected in the absence of a phenyl 
substituent. However, the 2-phenyl-substituted benzimidazole, 
13, -benzoxazole, 14, and -benzothiazole, 15, were all deuterated 
with good to excellent levels of incorporation using one of 
catalysts 1a±c. Once again, it was clear that 1a (containing the 
comparatively least electron-rich phosphine ligand, PPh3)
6
 was 
the most efficient and most generally applicable Ir catalyst. It 
should also be noted that, across the new substrates deuterated, 
catalyst series 1a±c ZDVVKRZQWREHPRUHDFWLYHWKDQ&UDEWUHH¶V
catalyst, 5, in eight of nine examples (see Experimental and ESI 
for details). In line with our previous studies,
5a,c
 this serves to 
show that the NHC/phosphine ligand sphere on these iridium(I) 
catalysts is more generally effective in such homogeneous HIE 
processes when compared to the pyridine/phosphine ligand 
sphere of classical catalyst, 5. 
Regio- and chemoselectivity is of fundamental and practical 
importance to the broadest range of C-H activation processes.
7
 
As such, the penultimate part of our study aimed to rank the 
relative electronic directing group capabilities of the N-
heterocycles employed within this programme. To achieve this, 
we conducted a series of competition experiments, employing  
 
Fig. 3. Deuteration of benzannulated N-heterocycles with catalysts 1a±c. 
Conditions: Substrate (0.086 mmol), [Ir] (0.0043 mmol, 5 mol%), DCM (1 
mL), D2 (1 atm), 25 ºC, 1 h. Deuterium incorporation measured by 
1H NMR 
and LC-MS (see ESI for details). The results shown are an average of two 
independent reaction runs. 
 
Table 1 
Competition experiments with phenyl N-heterocycles employing catalyst 1a.a 
 
  A 
  B 
7 8 9 10 11 
6 
  78 
28 
  87 
88 
  80 
77 
  30 
87 
  52 
52 
7 
   16 
76 
  81 
81 
  14 
84 
  73 
70 
8 
    90 
90 
  78 
86 
  88 
84 
9 
     43 
82 
  84 
85 
10 
      75 
63 
11 
 
 
    
 
aNumbers inside diagonalised cells represent overall %D for each substrate in 
competition experiments as determined by LC-MS. 
two substrates in one reaction vessel, along with the most 
generally active catalyst, 1a. Applying this methodology to 
simple N-heterocycles 6±11, we have estimated the relative 
directing group strength to be in the order: 7 > 9 ~ 11 > 6 > 8 > 
10 (Table 1) using a simple scoring system.
8
 This order is 
approximately proportional to the relative base strength of each 
substrate as determined by their pKaH values.
9
 However, the 
predicted order based on the collective was inconsistent with 
individual competition experiments, showing that each case of 
directing group competition must be treated separately rather 
than as part of an ensemble. 
 3 
Table 2 
Competition experiments with benzannulated N-heterocycles employing 
catalyst 1a.a 
 
     A 
        B 
13 14 15 
13 
   36 
34 
  26 
23 
14 
    69 
68 
7 
  57 
53 
  
8 
   93 
91 
 
11 
    84 
85 
aNumbers inside diagonalised cells represent overall %D for each substrate in 
competition experiments as determined by LC-MS. 
We then expanded this study to investigate the directing group 
ability of benzannulated substrates, 13±15 (Table 2, rows 1-2). In 
competition experiments between each benzannulated substrate 
(13 vs. 14, 13 vs. 15, and 14 vs. 15), almost equal deuterium 
incorporation was found in every case, suggesting closely 
comparable coordinating abilities or rapid substrate exchange at 
iridium in these cases. Interestingly, comparing the 
benzannulated substrates against their simpler analogues (7 vs. 
13, 8 vs. 14, and 11 vs. 15; Table 2, rows 3-5), closely equivalent 
deuterium incorporation was, again, observed in all cases. This 
infers that the increased size of the benzannulated substrates 
imparts only minimal steric encumbrance. 
In the final part of our study, we aimed to apply this emerging 
N-heterocyclic substrate applicability and understanding to the 
deuterium labelling of multifunctional, drug-like molecules from 
our available inventory. Accordingly, we investigated the 
labelling of oxazoles 16 and 17, and thiazole 18, using the 
optimal catalyst, 1a (Table 3). For the related oxazoles 16 and 17, 
good levels of both D-incorporation (in the expected positions) 
and isolated yields were achieved under the standard conditions 
in DCM (Entries 1 and 4). However, having previously shown 
that catalysts such as 1a operate across a wider solvent range,
5b,d 
we were able to improve on this initial success, finding that 
comparable or even higher levels of D-incorporation were 
possible in MeOH (Entries 2 and 5) and THF (Entries 3 and 6), 
albeit at slightly elevated temperatures in the latter solvent. 
Turning to thiazole derivative 18 (Entries 7±9), we were 
intrigued to observe no deuterium incorporation on the 
trifluoromethylated ring adjacent to the thiazole (position 1). 
Instead, labelling was observed solely adjacent to the alternative, 
oxadiazolone N-heterocycle in the molecule (position 2). This 
heterocycle is considered to be similar (but not identical) to 
Table 3 
Deuteration of drug-like heterocycles with catalyst 1a.a 
 
Entry Molecule Solvent Temp (°C) %D
b
 % Yield 
1  DCM 25 83 95 
2 16 MeOH 25 80 94 
3  THF 50 95 73 
4  DCM 25 82 90 
5 17 MeOH 25 85 90 
6  THF 50 95 93 
7
c
  DCM 25 -
d
 75 
8
c
 18 MeOH 25 66 77 
9
c
  THF 50 82 91 
aConditions: substrate  (22 µmol), 1a (5 mol%), solvent (1 mL), D2 (1atm), 1 
h. bPositions and percentage of deuterium incorporation determined by 1H 
NMR and confirmed by LC-MS. cPosition D2 only labeled. dSubstrate 18 was 
insoluble in DCM. 
imidazole due to the shared amidine-based directing group 
moiety. This labeling outcome is contrary to what may have been 
predicted on the basis of the single competition experiment using 
an imidazole and a thiazole (see Table 3, 7 vs. 11), but is in line 
with what would be predicted on the basis of the series of 
competition experiments from Table 1 overall (see determined 
general directing group order, vide supra). To show that 
competitive binding was directly influencing the labelling of 
substrate 18, we re-ran the reaction from Table 3, Entry 9 using 
25, 50, and 100 mol% 1a. Under these conditions (and by LC-
MS analysis), the molecule was increasingly deuterated across 
the three possible labelling sites instead of at just one site (see 
ESI for details). This suggests that, at higher catalyst loadings, 
the less favoured directing group has an enhanced possibility to 
coordinate the iridium catalyst. More broadly, these outcomes 
serve to reinforce our conclusions based on earlier computational 
studies.
7a
 Specifically, directing group chemoselectivity in 
multifunctional molecules in labelling with catalysts like 1a 
cannot be predicted on the basis of a sole competition experiment 
employing individual monofunctionalised molecules containing 
the various directing groups present in the single, multifunctional 
molecule.
7a,10
 This is particularly important when applying 
commonly low catalyst loadings of approximately 5 mol%. 
3. Conclusion 
In summary, we have shown that hydrogen isotope exchange 
catalysts 1a±c are compatible with an expanded array of 
pharmaceutically-relevant N-heterocyclic directing groups, 
namely pyrimidine, imidazole, oxazole, oxazoline, isoxazole, 
thiazole, benzimidazole, benzoxazole, and benzothiazole. 
Deuterium labelling of molecules containing these directing 
groups was achieved with high levels of incorporation and 
Tetrahedron 4 
excellent isolated yields, employing at least one of the 
commercialised catalysts 1a-c.
11
 From these studies, catalyst 1a 
has proven to be the most versatile and most broadly applicable. 
Employing this catalyst, competition studies between simple 
phenyl N-heterocycles revealed that directing group selectivity 
has to be considered on a case by case basis and cannot be 
predicted using a scoring system for the ensemble of competition 
experiments. This is especially important when considering 
multifunctional, drug-like compounds, as was demonstrated in 
the labelling of compound 18. Similar competition experiments 
employing benzannulated heterocycles revealed these species to 
compete equally with their parent heterocylce in reaction with the 
catalyst, such that: imidazole ~ benzimidazole; oxazole ~ 
benzoxazole; and thiazole ~ benzothiazole. As part of our future 
work, we are expanding this fundamental analysis of 
chemoselectivity to the deuterium and tritium labelling of a 
broader series of multifunctional drug compounds. 
4. Experimental section 
4.1. General information 
All substrates, catalysts, and solvents were obtained from 
commercial suppliers and used without further purification. All 
labelling reactions were carried out on a Heidolph Synthesis 1 
Liquid 16 device. Flash column chromatography was carried out 
using Merck kieselgel 60 silica gel (particle size: 63-200). 
1
H 
(300, 500 MHz) and 
13
C (75, 125 MHz) NMR spectra were 
obtained on Bruker spectrometers in the solvents indicated. 
Chemical shifts are reported in ppm. Coupling constants are 
reported in Hz and refer to 
3
JH-H couplings, unless otherwise 
stated. The distribution of hydrogen isotopes in the products was 
determined by a liquid chromatography-mass spectrometry (LC-
MS) system with a Symmetry Shield RP18 column, 3.9 x 150 
mm, with a gradient program. Column conditions are given in the 
ESI. 
4.2. General Procedures 
4.2.1. General Procedure A for Hydrogen Isotope 
Exchange with Simple Substrates 6 - 15 
The water inlet for the carousel reflux system was turned on 
prior to any further reaction set up. To a carousel tube was added 
the substrate of choice (0.086 mmol, unless otherwise stated) and 
iridium(I) catalyst (0.0043 mmol, 5 mol%, unless otherwise 
stated) under air. The desired solvent (1 mL) was added, rinsing 
the inner walls of the tube. The tube was then sealed at the screw 
cap (with gas inlet left open) under air before initiating the 
carousel shaking motion (720 rpm) and setting the reaction 
temperature (25 or 50 
o
C). The flask was twice evacuated and 
flushed with deuterium via a balloon. The carousel tube gas inlet 
was then closed, creating a sealed atmosphere of deuterium. After 
sealing the flask, the reaction timer was started, and a quick red 
to clear/yellow colour change was observed. The reaction 
mixture was stirred for 1 h before removing excess deuterium 
and replacing with air. The yellow solution was then washed with 
DCM and transferred to a single necked flask before removing 
the solvent under reduced pressure. The residue was filtered 
through a short plug of silica, eluting with ethyl acetate (2 x 3 
mL), and 2% MeOH where necessary, depending on the substrate 
of choice. An LC-MS sample (~2 µL) was taken directly from 
the combined filtered fractions. The solvent was evacuated again 
and the residue analysed directly by 
1
H NMR spectroscopy. The 
level and regioselectivity of deuterium incorporation in the 
substrate was determined by 
1
H NMR spectroscopy (for detail, 
see the ESI). Yields and %D incorporation are the averages of 
two reaction runs. 
 
4.2.2. General Procedure C for Hydrogen Isotope 
Exchange with Pharmaceuticals 16-18 with Catalyst 1a 
Following General Procedure A, each substrate was employed 
using 22 µmol in conjunction with 1.1 µmol of catalyst 1a (1.1 
mg, 5 mol%) and 1 mL solvent 
 
4.3. Hydrogen Isotope Exchange Experiments 
4.3.1. Hydrogen Isotope Exchange with Simple Substrates 
6 ± 15 
 
2-Phenylpyrimidine 6 
Following General Procedure A, exchange of 2-
phenylpyrimidine 6 (13.4 mg) in the presence of catalyst 1a (4.4 
PJJDYH>¶¶-2H2]-6 (12.8 mg, 96%, 93%D).
Following General Procedure A, exchange of 2-
phenylpyrimidine 6 (13.4 mg) in the presence of catalyst 1b (4.6 
PJJDYH>¶¶-2H2]-6 (12.4 mg, 93%, 42%D).
Following General Procedure A, exchange of 2-
phenylpyrimidine 6 (13.4 mg) in the presence of catalyst 1c (3.8 
PJJDYH>¶¶-2H2]-6 (12.8 mg, 96%, 14%D).
Following General Procedure A, exchange of 2-
phenylpyrimidine 6 (13.4 mg) in the presence of catalyst 5 (3.4 
PJJDYH>¶¶-2H2]-6 (11.6 mg, 86%, 28%D).
GH (400 MHz, CDCl3): 8.80 (d, 2H, J = 4.8 Hz), 8.44-8.41 (m, 
2H), 7.49-7.47 (m, 3H), 7.17 (t, 1H, J = 4.8 Hz). 
,QFRUSRUDWLRQH[SHFWHGDWį-8.41. 
,QFRUSRUDWLRQGHWHUPLQHGDJDLQVWį 
2-Phenylimidazole 7 
Following General Procedure A, exchange of 2-phenylimidazole 
7 (12.4 mg) in the presence of catalyst 1a PJJDYH>¶¶-
2
H2]-7 (11.7 mg, 94%, 89%D).
Following General Procedure A, exchange of 2-phenylimidazole 
7 (12.4 mg) in the presence of catalyst 1b (4.6 mg) gave [¶¶-
2
H2]-7 (11.2 mg, 91%, 73%D).
Following General Procedure A, exchange of 2-phenylimidazole 
7 (12.0 mg) in the presence of catalyst 1c PJJDYH>¶¶-
2
H2]-7 (12.8 mg, 95%, 70%D).
Following General Procedure A, exchange of 2-phenylimidazole 
7 (12.4 mg) in the presence of catalyst 5  PJ JDYH >¶¶-
2
H2]-7 (12.2 mg, 98%, 76%D). 
įH (300 MHz, DMSO-d6) 12.48 (bs, 1H), 7.94-7.92 (m, 2H), 7.43 
(t, 2H, J = 7.6 Hz), 7.32 (t, 1H, J  = 7.3 Hz), 7.13 (bs, 2H). 
,QFRUSRUDWLRQH[SHFWHGDWį-7.92. 
IncorpRUDWLRQGHWHUPLQHGDJDLQVWį. 
 
2-Phenyloxazole 8 
Following General Procedure A, exchange of 2-phenyloxazole 8 
(12.4 mg) in the presence of catalyst 1a  PJ JDYH >¶¶-
2
H2]-8 (10.0 mg, 80%, 92%D).
 5 
Following General Procedure A, exchange of 2-phenyloxazole 8 
(12.4 mg) in the presence of catalyst 1b  PJ JDYH >¶¶-
2
H2]-8 (9.8 mg, 79%, 79%D).
Following General Procedure A, exchange of 2-phenyloxazole 8 
(12.0 mg) in the presence of catalyst 1c  PJ JDYH >¶¶-
2
H2]-8 (8.6 mg, 70%, 91%D).
Following General Procedure A, exchange of 2-phenyloxazole 8 
(12.4 mg) in the presence of catalyst 5 PJJDYH>¶¶-2H2]-
8 (6.4 mg, 52%, 87%D). 
įH (300 MHz, MeOD-d4) 8.03-7.97 (m and overlapping s, 3H), 
7.50-7.48 (m, 3H), 7.29 (s, 1H). 
,QFRUSRUDWLRQH[SHFWHGDWį-7.97. 
,QFRUSRUDWLRQGHWHUPLQHGDJDLQVWį-7.48. 
 
2-Phenyloxazoline 9 
Following General Procedure A, exchange of 2-phenyloxazoline 
9 (12.6 mg) in the presence of catalyst 1a PJJDYH>¶¶-
2
H2]-9 (12.4 mg, 99%, 83%D).
Following General Procedure A, exchange of 2-phenyloxazoline 
9 (12.6 mg) in the presence of catalyst 1b PJJDYH>¶¶-
2
H2]-9 (11.8 mg, 94%, 75%D).
Following General Procedure A, exchange of 2-phenyloxazoline 
9 (12.6 mg) in the presence of catalyst 1c PJJDYH>¶¶-
2
H2]-9 (11.8 mg, 94%, 80%D).
Following General Procedure A, exchange of 2-phenyloxazoline 
9 (12.6 mg) in the presence of catalyst 5 (3.4 PJ JDYH >¶¶-
2
H2]-9 (2.8 mg, 23%, 76%D). 
įH (300 MHz, CDCl3) 7.95-7.92 (m, 2H), 7.49-7.24 (m, 3H), 4.37 
(t, 2H, J = 9.6 Hz), 4.00 (t, 2H, J = 9.6 Hz) 
,QFRUSRUDWLRQH[SHFWHGDWį-7.92. 
,QFRUSRUDWLRQGHWHUPLQHGDJDLQVWį 
 
5-Phenylisoxazole 10 
Following General Procedure A, exchange of 5-phenylisoxazole 
10 (12.4 mg) in the presence of catalyst 1a PJJDYH>¶¶-
2
H2]-10 (11.6 mg, 93%, 86%D).
Following General Procedure A, exchange of 5-phenylisoxazole 
10 (12.4 mg) in the presence of catalyst 1b PJJDYH>¶¶-
2
H2]-10 (12.4 mg, 100%, 95%D).
Following General Procedure A, exchange of 5-phenylisoxazole 
10 (12.4 mg) in the presence of catalyst 1c PJJDYH>¶¶-
2
H2]-10 (12.0 mg, 95%, 89%D).
Following General Procedure A, exchange of 5-phenylisoxazole 
10 (12.4 mg) in the presence of catalyst 5 PJJDYH>¶¶-
2
H2]-10 (9.0 mg, 73%, 54%D). 
įH (300 MHz, DMSO-d6) 9.01 (d, 1H, J = 1.7 Hz), 7.91-7.88 (m, 
2H), 7.56-7.50 (m, 3H), 7.16 (d, 1H, J = 1.7 Hz). 
,QFRUSRUDWLRQH[SHFWHGDWį-7.88. 
,QFRUSRUDWLRQGHWHUPLQHGDJDLQVWį 
 
 
 
2-Phenylthiazole 11 
Following General Procedure A, exchange of 2-phenylthiazole 
11 (13.8 mg) in the presence of catalyst 1a PJJDYH>¶¶-
2
H2]-11 (12.2 mg, 89%, 82%D).
Following General Procedure A, exchange of 2-phenylthiazole 
11 (13.8 mg) in the presence of catalyst 1b PJJDYH>¶¶-
2
H2]-11 (11.0 mg, 80%, 44%D).
Following General Procedure A, exchange of 2-phenylthiazole 
11 (13.8 mg) in the presence of catalyst 1c PJJDYH>¶¶-
2
H2]-11 (13.6 mg, 98%, 72%D).
Following General Procedure A, exchange of 2-phenylthiazole 
11 (13.8 mg) in the presence of catalyst 5 PJJDYH>¶¶-
2
H2]-11 (10.8 mg, 78%, 59%D). 
įH (300 MHz, DMSO-d6) 7.97-7.93 (m, 3H), 7.78 (d, 1H, J = 3.3 
Hz), 7.54-7.48 (m, 3H). 
,QFRUSRUDWLRQH[SHFWHGDWį-7.93. 
,QFRUSRUDWLRQGHWHUPLQHGDJDLQVWį-7.48 
 
Benzimidazole 12 
Following General Procedure A, exchange of benzimidazole 12 
(10.2 mg) in the presence of catalyst 1a (4.4 mg) gave 
benzimidazole 12 (10.0 mg, 99%, 0%D).
Following General Procedure A, exchange of benzimidazole 12 
(10.2 mg) in the presence of catalyst 1b (4.6 mg) gave 
benzimidazole 12 (10.0 mg, 99%, 0%D).
Following General Procedure A, exchange of benzimidazole 12 
(10.2 mg) in the presence of catalyst 1c (3.8 mg) gave 
benzimidazole 12 (10.0 mg, 99%, 0%D).
Following General Procedure A, exchange of benzimidazole 12 
(10.2 mg) in the presence of catalyst 5 (3.4 mg) gave 
benzimidazole 12 (10.0 mg, 99%, 0%D). 
įH (300 MHz, DMSO-d6) 8.15 (s, 1H, H3), 7.62-7.59 (m, 2H, H2), 
7.29-7.23 (m, 2H, H
1
). 
No incorporation expected. 
 
2-Phenylbenzimidazole 13 
Following General Procedure A, exchange of 2-
phenylbenzimidazole 13 (16.8 mg) in the presence of catalyst 1a 
(4.4 mg) gave >¶¶-2H2]-13 (14.8 mg, 88%, 84%D).
Following General Procedure A, exchange of 2-
phenylbenzimidazole 13 (16.8 mg) in the presence of catalyst 1b 
(4.6 mg) gave >¶¶-2H2]-13 (14.9 mg, 89%, 83%D).
Following General Procedure A, exchange of 2-
phenylbenzimidazole 13 (16.8 mg) in the presence of catalyst 1c 
(3.8 mg) gave >¶¶-2H2]-13 (13.8 mg, 82%, 72%D).
Following General Procedure A, exchange of 2-
phenylbenzimidazole 13 (16.8 mg) in the presence of catalyst 5 
(3.4 mg) gave >¶¶-2H2]-13 (15.3 mg, 91%, 72%D). 
įH (300 MHz, DMSO-d6) 12.90 (s, 1H), 8.19-8.17 (m, 2H), 7.60-
7.47 (m, 5H), 7.23-7.18 (m, 2H). 
IQFRUSRUDWLRQH[SHFWHGDWį-8.17. 
,QFRUSRUDWLRQGHWHUPLQHGDJDLQVWį-7.18. 
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2-Phenylbenzoxazole 14 
Following General Procedure A, exchange of 2-
phenylbenzoxazole 14 (16.8 mg) in the presence of catalyst 1a 
(4.4 mg) gave >¶¶-2H2]-14 (15.2 mg, 94%, 90%D).
Following General Procedure A, exchange of 2-
phenylbenzoxazole 14 (16.8 mg) in the presence of catalyst 1b 
(4.6 mg) gave >¶¶-2H2]-14 (16.2 mg, 96%, 82%D).
Following General Procedure A, exchange of 2-
phenylbenzoxazole 14 (16.8 mg) in the presence of catalyst 1c 
(3.8 mg) gave >¶¶-2H2]-14 (16.0 mg, 95%, 80%D).
Following General Procedure A, exchange of 2-
phenylbenzoxazole 14 (16.8 mg) in the presence of catalyst 5 
(3.4 mg) gave >¶¶-2H2]-14 (16.2 mg, 96%, 96%D). 
įH (300 MHz, MeOD-d4) 8.23-8.20 (m, 2H), 7.73-7.70 (m, 1H), 
7.67-7.64 (m, 1H), 7.59-7.53 (m, 3H), 7.43-7.36 (m, 2H). 
,QFRUSRUDWLRQH[SHFWHGDWį-8.20. 
,QFRUSRUDWLRQGHWHUPLQHGDJDLQVWį-7.36. 
 
2-Phenylbenzothiazole 15 
Following General Procedure A, exchange of 2-
phenylbenzothiazole 15 (18.2 mg) in the presence of catalyst 1a 
(4.4 mg) gave >¶¶-2H2]-15 (18.0 mg, 99%, 94%D).
Following General Procedure A, exchange of 2-
phenylbenzothiazole 15 (18.2 mg) in the presence of catalyst 1b 
(4.6 mg) gave >¶¶-2H2]-15 (17.0 mg, 93%, 60%D).
Following General Procedure A, exchange of 2-
phenylbenzothiazole 15 (18.2 mg) in the presence of catalyst 1c 
(3.8 mg) gave >¶¶-2H2]-15 (17.2 mg, 95%, 31%D).
Following General Procedure A, exchange of 2-
phenylbenzothiazole 15 (18.2 mg) in the presence of catalyst 5 
(3.4 mg) gave >¶¶-2H2]-15 (17.2 mg, 95%, 81%D). 
įH (300 MHz, CDCl3) 8.10-8.05 (m, 3H), 7.90 (d, 1H, J = 9.0 
Hz), 7.50-7.46 (m, 4H), 7.40-7.35 (m, 1H). 
,QFRUSRUDWLRQH[SHFWHGDWį-8.05. 
,QFRUSRUDWLRQGHWHUPLQHGDJDLQVWį-7.35. 
 
4.3.2. Hydrogen Isotope Exchange of Drug-like 
Heterocycles 16-18 with Catalyst 1a 
Oxazole 16 
Following General Procedure C, exchange of pharmaceutical 16 
(8.4 mg) in the presence of catalyst 1a (1.1 mg) in DCM (1 mL) 
at 25 °C gave [
2
H2]-16 (8.0 mg, 95%, 83%D; see Table 3 for 
position of D incorporation). 
Following General Procedure C, exchange of pharmaceutical 16 
(8.4 mg) in the presence of catalyst 1a (1.1 mg) in MeOH (1 mL) 
at 25 °C gave [
2
H2]-16 (7.9 mg, 94%, 80%D; see Table 3 for 
position of D incorporation). 
Following General Procedure C, exchange of pharmaceutical 16 
(8.4 mg) in the presence of catalyst 1a (1.1 mg) in THF (1 mL) at 
50 °C gave [
2
H2]-16 (6.1 mg, 73%, 95%D; see Table 3 for 
position of D incorporation). 
įH (300 MHz, DMSO-d6) 13.08 (s, 1H), 8.13 (s, 1H), 7.99-7.95 
(m, 2H), 7.54-7.52 (m, 3H), 7.29-7.16 (m, 3H), 4.47 (s, 2H), 4.40 
(s, 2H), 3.54 (t, 2H, J = 6.5 Hz), 3.45 (t, 2H, J = 6.5 Hz), 2.29 (s, 
3H), 1.78 (quintet, 2H, J = 6.5 Hz). 
,QFRUSRUDWLRQH[SHFWHGDWį-7.95. 
,QFRUSRUDWLRQGHWHUPLQHGDJDLQVWį 
 
Oxazole 17 
Following General Procedure C, exchange of pharmaceutical 17 
(9.9 mg) in the presence of catalyst 1a (1.1 mg) in DCM (1 mL) 
at 25 °C gave [
2
H2]-17 (8.9 mg, 90%, 82%D; see Table 3 for 
position of D incorporation). 
Following General Procedure C, exchange of pharmaceutical 17 
(9.9 mg) in the presence of catalyst 1a (1.1 mg) in MeOH (1 mL) 
at 25 °C gave [
2
H2]-17 (8.9 mg, 90%, 85%D; see Table 3 for 
position of D incorporation). 
Following General Procedure C, exchange of pharmaceutical 17 
(9.9 mg) in the presence of catalyst 1a (1.1 mg) in THF (1 mL) at 
50 °C gave [
2
H2]-17 (9.2 mg, 93%, 95%D; see Table 3 for 
position of D incorporation). 
įH (300 MHz, DMSO-d6) 13.06 (s, 1H), 7.81 (d, 2H, J = 8.2 Hz), 
7.33-7.16 (m, 5H), 4.53 (s, 2H), 4.39 (s, 2H), 2.37-2.36 
(overlapping singlets, 6H), 2.29 (s, 3H). 
,QFRUSRUDWLRQH[SHFWHGDWį 
,QFRUSRUDWLRQGHWHUPLQHGDJDLQVWį 
 
Thiazole-oxadiazolone 18 
Following General Procedure C, exchange of pharmaceutical 18 
(10.2 mg) in the presence of catalyst 1a (1.1 mg) in DCM (1 mL) 
at 25 °C returned 18 (7.7 mg, 75%, 0%D). 
Following General Procedure C, exchange of pharmaceutical 18 
(10.2 mg) in the presence of catalyst 1a (1.1 mg) in MeOH (1 
mL) at 25 °C gave [
2
H]-18 (7.9 mg, 77%, 66%D; see Table 3 for 
position of D incorporation). 
Following General Procedure C, exchange of pharmaceutical 18 
(10.2 mg) in the presence of catalyst 1a (1.1 mg) in THF (1 mL) 
at 50 °C gave [
2
H]-18 (9.3 mg, 91%, 82%D; see Table 3 for 
position of D incorporation). 
įH (300 MHz, DMSO-d6) 12.79 (s, 1H), 8.13 (d, 2H, J = 8.1 Hz), 
7.86 (d, 2H, J = 8.1 Hz), 7.67 (d, 1H, J = 8.7 Hz), 7.44 (d, 1H, J 
= 2.5 Hz), 7.23 (dd, 1H, 
3
J = 8.7 Hz, 
4
J = 2.5 Hz), 5.51 (s, 2H), 
2.50 (s, ~3H, overlapping with residual DMSO). 
Incorporation possible DW į  observed as detailed by that 
shown in Table 3, Entries 7 ± 9), and 8.13. 
,QFRUSRUDWLRQGHWHUPLQHGDJDLQVWį 
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